Longboard pharmaceuticals to present late-breaking data from the pacific study at the american academy of neurology (aan) annual meeting on april 15

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that dr. randall kaye, longboard's chief medical officer, will present late-breaking data from the pacific study evaluating bexicaserin, an oral, centrally acting 5-ht2c receptor superagonist, in participants with developmental and epileptic encephalopathies (dees) at the aan.
LBPH Ratings Summary
LBPH Quant Ranking